A bariatric surgery consultation is not a commitment , it's a conversation about your weight loss options
Future studies with specific outcomes, larger sample sizes, different ages, taking into consideration baseline glutathione levels, are needed to better assess treatment outcomes
Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health. The FDAs decision is largely based on data from the SELECT trial, which included more than 17,000 overweight or obese patients with a baseline age of 45 years old
Because retatrutide is still investigational, important unanswered questions remain about long-term cardiovascular effects, durability of weight loss, ongoing tolerability, and safety across broader patient populations, which is one reason reputable clinics, including Relive Health centers nationwide, are not offering retatrutide at this time